Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

Karla Hernández-Villafuerte, PhD

Karla Hernández-Villafuerte, PhD

Karla Hernández-Villafuerte, PhD

Position:

Researcher

E-mail:

k.hernandezvillafuerte@dkfz.de

Phone 1:

+49 6221 42-1913

Phone 2:

+49 6221 42-1919

Dr. Karla Hernandez-Villafuerte is an economist and an econometrician with wide experience in the examination of the factors influencing the decision making process for the reimbursement of new medicines. She is currently working on assessing the efficacy of the multi-attribute utility instruments that reflect quality of life of cancer patients. Additionally, she has an active role in the leadership and execution of a project designed to investigate the determinants of the Research and Development (R&D) costs of a new successful medicine.

Before joining the DKFZ, Karla was part of the Office of Health Economics (OHE) in London. Her work at the OHE included a variety of research projects, for example, the evaluation of statistical and health economic issues on the context of extrapolating from progression-free survival to overall survival in oncology; and the analysis of the evolution of HTA in developing countries (within the International Decision Support Initiative (iDSI)). She has a PhD in Economics from the University of Göttingen in Germany and a master's degree in economics from the University of Costa Rica.

 

Selected Publications

M. Schlander, K. Hernandez-Villafuerte, C. -Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:
How much does it cost to research and develop a new drug? A systematic review and assessment.
Pharmacoeconomics, (2021) 39(11) 1243-1269.
DOI: 10.1007/s40273-021-01065-y.

K. Hernandez-Villafuerte, A. Fischer, N. R. Latimer:
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology.
International Journal of Technology Assessment in Health Care, (2018) 34(3) 300-316.
DOI: 10.1017/S0266462318000338.

K. Hernandez-Villafuerte, J. Sussex, E. Robin, S. Guthrie, S. Wooding:
Economies of scale and scope in publicly funded biomedical and health research: Evidence from the literature.
Health Research Policy and Systems, (2017) 15(3).
DOI 10.1186/s12961-016-0167-3.

to top
powered by webEdition CMS